Traditional Chinese medicine composition for relieving cough and reducing sputum and preparation method thereof

Abstract

The invention relates to a traditional Chinese medicine composition for relieving cough and reducing sputum and a preparation method thereof, and the traditional Chinese medicine composition for relieving cough and reducing sputum is prepared from the following raw materials in parts by weight: 9-11 parts of radix peucedani, 9-11 parts of platycodon grandiflorum, 7-9 parts of ginger bamboo shavings, 8-10 parts of tabasheer and 9-15 parts of bryozoatum. According to the preparation method, the traditional Chinese medicine composition is prepared into granules, and the granules have a good treatment effect on patients suffering from thick expectoration, chest distress and reversed flow of qi due to phlegm-heat obstructing lung of chronic bronchitis.

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a traditional Chinese medicine composition for relieving cough and reducing phlegm and a preparation method thereof. Background Art

[0002] Chronic bronchitis with phlegm-heat obstructing the lungs is a common syndrome during acute exacerbations of chronic bronchitis. Patients with this syndrome often produce thick, yellow-green sputum that is difficult to cough up, accompanied by symptoms such as chest tightness and shortness of breath. There is a noticeable sense of pressure in the chest that worsens with activity and is accompanied by rapid breathing or wheezing. In severe cases, the face may flush and the breathing may become heavy. Signs of heat are also prominent, manifested by dry mouth, thirst, dry and hard stools, a red tongue with a greasy yellow coating, and a slippery and rapid pulse. Currently, classic prescriptions for treating chronic bronchitis with heat-obstructing the lungs include Qingjin Huatan Decoction and Dingchuan Decoction. Qingjin Huatan Decoction is composed of over 10 medicinal herbs, including Scutellaria baicalensis, Gardenia jasminoides, Trichosanthes kirilowii, and Fritillaria cirrhosa. The active ingredients are unclear, and Trichosanthes kirilowii and Fritillaria cirrhosa are expensive and easily substituted with inferior herbs, resulting in fluctuating efficacy. Dingchuan Decoction uses a relatively high dosage of ephedra, and the ephedrine in it can increase blood pressure and heart rate, potentially inducing angina pectoris in patients with coronary heart disease and arrhythmias. Common Chinese patent medicines like Chuanbei Loquat Paste and Qingqi Huatan Pills also have drawbacks. Chuanbei Loquat Paste primarily uses Fritillaria cirrhosa to moisten the lungs and loquat leaves to reduce adverse reactions, but lacks a potent heat-clearing agent. It is less effective for acute phlegm-heat syndromes such as high fever, thick yellow sputum, chest tightness, and shortness of breath, requiring combination use with antibiotics or mucolytics. The main ingredient in Qingqi Huatan Pills, Arisaema consanguineum, is made from toxic raw Arisaema consanguineum, which is processed with bile to reduce its toxins. Improper processing can produce unconverted toxins that irritate the airways and exacerbate coughs. Summary of the Invention

[0003] In order to make up for the deficiencies of the existing technology, the present invention provides a traditional Chinese medicine composition for relieving cough and reducing phlegm and a preparation method thereof. The prescription is a clinical experience prescription of Professor Zhang Wei, a well-known expert in pulmonary disease at Shandong Provincial Hospital of Traditional Chinese Medicine, and is suitable for patients with chronic bronchitis, phlegm-heat obstructing the lungs, coughing up thick phlegm, chest tightness and qi reversal.

[0004] The technical solution adopted by the present invention to solve the above technical problems is:

[0005] A traditional Chinese medicine composition for relieving cough and reducing phlegm is prepared from the following raw materials in parts by weight: 9-11 parts of peucedanum chinense, 9-11 parts of platycodon grandiflorum, 7-9 parts of rhizoma zingiberis, 8-10 parts of rhizoma jasminoides and 9-15 parts of pumice.

[0006] Preferably, the invention is prepared from the following raw materials in parts by weight: 9 parts of Peucedanum chinense, 9 parts of Platycodon grandiflorum, 9 parts of Rhizoma Zingiberis, 9 parts of Radix Glehniae and 9 parts of Pumice.

[0007] Preferably, the Chinese medicine composition is prepared into an oral preparation, which is an oral liquid, granules, lyophilized powder, tablets, capsules or pills.

[0008] In addition, the present application also provides a method for preparing a Chinese medicine composition for relieving cough and reducing phlegm.

[0009] The oral preparation is a lyophilized powder, and its preparation method is as follows:

[0010] A1 Take Tianzhuhuang slices, place them in a casserole, add 12 times the amount of water and soak for 30 minutes;

[0011] A2: Place Platycodon grandiflorum, Peucedanum chinense, Rhizoma Zingiberis, and Pumice in another casserole, add 12 times the amount of water, and soak for 30 minutes;

[0012] A3 decocts the soaking liquid with medicinal herbs in A1, brings it to a boil over high heat, then simmers it for 10 minutes. Add the soaking liquid with medicinal herbs in A2 to the casserole and simmer together, brings it to a boil over high heat, then simmers it for 20 minutes, and filters it while it is hot.

[0013] A4: Add 10 times the amount of water to the residue obtained in A3, boil over high heat, then simmer for another 20 minutes. Filter while hot, combine the filtrate with the filtrate in A3, concentrate at 60°C, and freeze-dry in a vacuum oven to obtain the product.

[0014] The oral preparation is a granule, and its preparation method is as follows: it is prepared from granules of Peucedanum chinense, Platycodon grandiflorum, Rhizoma Zingiberis, Radix Glycyrrhizae, and Pumice.

[0015] The present invention adopts the above structure and has the advantages that:

[0016] The Chinese medicine composition provided by the present invention, Radix Platycodonis is bitter, pungent, slightly cold, returns to lung meridian, descends qi and resolves phlegm, dispels wind and clears heat, is used for phlegm-heat wheezing, coughs up yellow and thick sputum, and coughs with wind-heat and has a lot of sputum, and is a monarch drug. Radix Platycodonis dispersing the lung and eliminating phlegm, carries medicine upward, helps Radix Platycodonis regulate lung qi (dispersing and descending due to each other), Radix Glycyrrhizae clears heat and dispels phlegm, targets the yellow sticky phlegm of phlegm-heat cementation, strengthens the power of monarch drug to resolve phlegm, and is a ministerial drug. In addition, Radix Platycodonis can also draw various medicines into lung meridian, plays the effect of dispersing lung and expelling phlegm and is concurrently a making drug. Rhizoma Zingiberis Recens soothes the stomach and resolves phlegm, and controls the cold property of Radix Glycyrrhizae and Pumice Stone concurrently, prevents injury to the spleen and stomach, and Pumice Stone softens old phlegm, dilutes sticky phlegm, and assists phlegm to be discharged, and is an adjuvant. This prescription uses hu hu and platycodon to promote and descend lung qi, while ginger, bamboo shavings, and pumice stone clear away heat and resolve phlegm, which together have the effect of resolving phlegm, relieving cough, and regulating qi. It is suitable for patients with chronic bronchitis who have phlegm-heat blocking the lungs and cough with thick phlegm, chest tightness, and shortness of breath.

[0017] In summary, the Chinese medicine composition for relieving cough and reducing phlegm provided by the present invention has strict compatibility and concise formula, can effectively improve the viscosity of sputum of patients, and has a good therapeutic effect on patients with chronic bronchitis, phlegm-heat obstructing the lungs, coughing up thick sputum, chest tightness and qi reversal. DETAILED DESCRIPTION

[0018] In order to clearly illustrate the technical features of this solution, the present invention is described in detail below through specific implementation methods.

[0019] 1 Instruments and reagents

[0020] SA224S-CW electronic balance and XS105 electronic balance were purchased from Sartorius Scientific Instrument Co., Ltd.; TG-20M medical centrifuge was purchased from Hunan Pingfan Technology Co., Ltd.

[0021] Capsaicin (batch number 701N022) was purchased from Beijing Solebeau Technology Co., Ltd.; RAT IL-6, IL-8, and TNF-α ELISA Kit (batch number E20221201A) was purchased from Suzhou Calvin Biotechnology Co., Ltd.; sodium carboxymethyl cellulose (batch number 2311001) was purchased from Shandong Liaocheng Anxin Pharmaceutical Excipients Co., Ltd.; and phenol red (batch number HG / T4100-2009) was purchased from Tianjin Komiou Chemical Reagent Co., Ltd.

[0022] 2 Exploring the effects of the components and ratios of traditional Chinese medicine compositions on experimental results through animal experiments

[0023] 2.1 Test Drugs

[0024] Experimental sample: the Chinese medicine composition of the present application (Huatansan Granules, batch number 20230113).

[0025] Comparative sample 1: There is no Peucedanum chinense in the prescription, and the rest is the same as the experimental sample (batch number 20230201).

[0026] Comparative sample 2: There is no pumice in the prescription, and the rest is the same as the experimental sample (batch number 20230201).

[0027] Comparative sample 3: The radix peucedanum in the prescription was replaced with radix scutellariae, and the rest was the same as the experimental sample (batch number 20230201).

[0028] Comparative sample 4: 10 parts by weight of loquat leaves were additionally added to the formula, and the rest were the same as the experimental sample (batch number 20230201).

[0029] Comparative sample 5: The raw material composition of pumice in the prescription is 20 parts by weight, and the other components are the same as those of the experimental sample (batch number 20230201).

[0030] Control sample 1: Pentotheline Citrate Tablets (Batch No. 210531), purchased from Xinmingbo Pharmaceutical Group Co., Ltd.

[0031] Control sample 2: Ambroxol hydrochloride tablets (batch number 622122014), purchased from Shandong Yuxin Pharmaceutical Co., Ltd.

[0032] 2.2 Experimental animals

[0033] Ninety SPF-grade SD rats, half male and half female, weighing 200-220 g; 80 KM mice, half male and half female, weighing 18-22 g, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd., license number: SCXK(Lu)20220006, maintained at a temperature of 23-26°C, and used in this experiment after adaptive feeding for 5 days.

[0034] 2.3 Experimental methods

[0035] 2.3.1 Capsaicin-induced cough experiment

[0036] 90 rats (half male and half female) were selected and randomly divided into 9 groups: blank group, model group, treatment group (experimental sample, 1.80 g / kg), comparative group 1 (comparative sample 1, 1.44 g / kg), comparative group 2 (comparative sample 2, 1.44 g / kg), comparative group 3 (comparative sample 3, 1.80 g / kg), comparative group 4 (comparative sample 4, 2.16 g / kg), comparative group 5 (comparative sample 5, 2.16 g / kg), and positive control group (control sample 1, 9.0 mg / kg), with 10 rats in each group. Drug administration began on the day of grouping. The blank group and model group were gavage-administered 0.5% CMC-Na solution, while the remaining groups were given suspensions of the corresponding concentrations, with a dosing volume of 20 mL / kg, once daily for 14 consecutive days. Immediately after the last administration, the rats were placed in a transparent sealed container. Except for the blank group, 0.3 mL of 0.1 mmol / L capsaicin was sprayed into the container using an ultrasonic nebulizer for 2 minutes. The cough latency and the number of coughs within 10 minutes were recorded.

[0037] 2.3.2 Phenol red excretion test

[0038] Eighty quarantined mice, half male and half female, were randomly divided into eight groups: a blank group, a treatment group (experimental sample, 0.26 g / kg), a comparative group 1 (comparative sample 1, 0.21 g / kg), a comparative group 2 (comparative sample 2, 0.21 g / kg), a comparative group 3 (comparative sample 3, 0.26 g / kg), a comparative group 4 (comparative sample 4, 0.31 g / kg), a comparative group 5 (comparative sample 5, 0.31 g / kg), and a positive control group (control sample 2, 15.6 mg / kg). Each group received drug administration starting on the day of grouping. The blank group received oral administration of 0.5% CMC-Na solution, while the remaining groups received suspensions of the corresponding concentrations at a volume of 20 mL / kg. Drug administration was performed once daily for 14 consecutive days. Thirty minutes after the last dose, mice in each group were intraperitoneally injected with 5% phenol red solution (0.1 mL / 10 g). Thirty minutes later, the mice were sacrificed by cervical dislocation, and the trachea was isolated. The same length of trachea from the thyroid cartilage to the tracheal bifurcation was taken from each rat and placed in a test tube containing 3 mL of normal saline. 0.1 mL of sodium hydroxide (1 mol / L) was added and the optical density (OD) value was measured at a wavelength of 546 nm. The phenol red content was calculated using a standard curve.

[0039] 2.4 Serum sample collection

[0040] Serum samples were collected from the rats described in 2.3.1. The rats were fasted with water but not food the night before sample collection. Two hours after oral administration on the 14th day, blood was collected from the rats' orbits and centrifuged at 8000 rpm for 10 minutes. The supernatant was collected. Serum samples were analyzed for IL-6, IL-8, and TNF-α levels in the serum of each group of rats using ELISA according to the kit instructions.

[0041] 2.5 Statistical analysis

[0042] Data are expressed as mean ± standard deviation (mean ± SD) and analyzed using SPSS 21.0 software. Two independent samples were analyzed by one-way ANOVA. P < 0.05 was considered statistically significant.

[0043] 2.6 Experimental Results

[0044] 2.6.1 Effect of Huatansan on the Cough Latency and Cough Frequency of Capsaicin-Induced Cough in Rats

[0045] As shown in Table 1, compared with the blank group, the model group rats had a significantly increased number of coughs (P < 0.01). Compared with the model group, the Huatan San treatment group, the positive control group, comparative group 2, comparative group 3, comparative group 4, and comparative group 5 all significantly reduced the number of coughs in rats (P < 0.01). There was no statistical difference between comparative group 1 and the model group (P > 0.05). Compared with the model group, the Huatan San treatment group, the positive control group, comparative group 4, and comparative group 5 all significantly prolonged the cough latency (P < 0.01). Comparative groups 2 and 3 could prolong the cough latency, with statistical differences (P < 0.05). There was no statistical difference between comparative group 1 and the model group (P > 0.05). The results showed that the Huatan San treatment group and the positive control group significantly reduced the number of coughs in rats and prolonged the cough latency. Comparative groups 1-5 had a certain improvement effect, but the efficacy was not as good as that of the Huatan San treatment group.

[0046] Table 1 Statistical results of rat cough latency and frequency

[0047]

[0048]

[0049] Note: Compared with the blank group, ## P<0.01; compared with the model group, ** P<0.01, * P<0.05

[0050] 2.6.2 Effect of Huatansan on phenol red secretion in mouse trachea

[0051] Compared with the blank group, the phenol red secretion of the Huatansan treatment group, comparative groups 1-5 and the positive control group was significantly increased (P < 0.01), proving that Huatansan has an expectorant effect.

[0052] Table 2 Effects of Huatansan on phenol red secretion in mouse trachea

[0053]

[0054] Note: Compared with the blank group, ** P<0.01, * P<0.05

[0055] 2.6.3 Effect of Huatansan on Serum Cytokines in Rat Model of Capsaicin Mist-Induced Cough

[0056] As shown in Table 3, IL-6, IL-8, and TNF-α levels were significantly increased in the model group compared with the blank group (P < 0.01). Compared with the model group, IL-6, IL-8, and TNF-α levels in the Huatan San treatment group and the positive control group were significantly decreased (P < 0.01). Compared with the model group, the serum IL-6, IL-8, and TNF-α levels of rats in control groups 1-5 also decreased, but the downward trend was less pronounced than in the Huatan San treatment group. These results suggest that Huatan San may exert its antitussive effect by inhibiting the levels of inflammatory factors such as IL-6, IL-8, and TNF-α in rat serum, alleviating the inflammatory response, and thus exerting its antitussive effect.

[0057] Table 3 Effects of Huatansan on serum IL-6, IL-8, and TNF-α levels in rats (x±s)

[0058]

[0059] Note: Compared with the blank group, ## P<0.01; compared with the model group, ** P<0.01

[0060] 3Clinical trials

[0061] 3.1 Diagnostic criteria

[0062] The diagnostic criteria for chronic bronchitis were formulated based on the "Clinical Diagnosis and Efficacy Assessment Criteria for Chronic Bronchitis" revised by the National Chronic Bronchitis Clinical Professional Conference and the "Guidelines for the Diagnosis and Treatment of Cough" of the Respiratory Diseases Branch of the Chinese Medical Association.

[0063] Chronic bronchitis can be diagnosed if the main clinical symptoms are cough and sputum production, or accompanied by wheezing, which persist for three months each year for two or more consecutive years, and if other diseases with cough, sputum, and wheezing (such as pneumoconiosis, tuberculosis, bronchiectasis, bronchial asthma, lung abscess, heart failure, and lung cancer) are excluded. A diagnosis can also be made for patients who have cough, sputum, and wheezing for two or more consecutive years, but whose annual symptoms last less than three months, if there is clear objective evidence (such as X-rays).

[0064] Syndrome diagnostic criteria: refer to the cough and phlegm-heat syndrome in the "Chinese Medicine Pediatrics" edited by Wang Shouchuan and published by China Traditional Chinese Medicine Press, and the phlegm-heat lung obstruction syndrome in the "Guidelines for the Diagnosis and Treatment of Pediatric Bronchitis in Traditional Chinese Medicine" written by Li Yanning et al.

[0065] Phlegm-heat syndrome: Coughing with a lot of phlegm (main symptom), which is yellow and sticky and difficult to cough up, or even gurgling in the throat, fever, thirst, red face and irritability, short and dark urine, dry and hard stools, red tongue with yellow and greasy coating, slippery and rapid pulse or purple and stagnant fingerprints.

[0066] Note: The main symptoms are required, and the secondary items must be ≥2, and combined with the tongue coating and pulse condition, a diagnosis can be made.

[0067] 3.2 Selection of test subjects

[0068] 3.2.1 Inclusion criteria

[0069] (1) Patients with chronic bronchitis who have not used expectorant drugs within 24 hours;

[0070] (2) Traditional Chinese Medicine differentiation of phlegm-heat obstructing the lungs;

[0071] (3) Age 18–60 years old;

[0072] (4) The subjects can communicate well with the researchers, fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign a written informed consent.

[0073] 3.2.2 Exclusion criteria

[0074] (1) Clinically diagnosed with severe or critical lung disease;

[0075] (2) Those who are allergic to the ingredients of the experimental drugs and the equipment used;

[0076] (3) Patients with peptic ulcer, bronchiectasis with hemoptysis, sinusitis, severe pulmonary hypertension (heart function ≥ grade III), severe pneumonia (requiring ICU comprehensive treatment), and severe respiratory failure requiring ventilator (invasive or non-invasive) auxiliary treatment;

[0077] (4) Patients who are unable to cough up sputum (such as those who are bedridden for a long time or have advanced lung cancer);

[0078] (5) Patients who had used cough and expectorant Chinese and Western medicines within 24 hours (including 24 hours) before enrollment;

[0079] (6) Patients who used systemic hormones within 24 hours (including 24 hours) before enrollment;

[0080] (7) Past or current history of any of the following major diseases or conditions that may affect the study evaluation: 1) History of cerebrovascular accident within the past 6 months, such as ischemic stroke and hemorrhagic stroke; 2) History of unstable angina, myocardial infarction, or acute heart failure within the past 6 months; 3) Sick sinus syndrome, II-III degree atrioventricular block, atrial flutter, atrial fibrillation, and other malignant or potentially malignant arrhythmias; 4) Large aneurysm or dissecting aneurysm, major cardiac surgery, or cardiovascular intervention within 6 months; 5) Patients with severe liver disease or liver dysfunction (such as cirrhosis, chronic active hepatitis, etc.); 6) Patients with severe kidney disease (such as chronic renal insufficiency (stage II and above), renal artery stenosis, etc.); 7) History of malignant tumor (except any carcinoma in situ and malignant lung nodules that have been resected and have not recurred for 5 years, and stable basal cell or squamous cell carcinoma of the skin); 8) Patients with immunodeficiency diseases or taking immunosuppressants; 9) Patients with severe primary hematopoietic diseases or agranulocytosis;

[0081] (8) Any of the following laboratory test indicators met the following criteria before enrollment: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 times the upper limit of normal (ULN) (refer to the normal range of laboratory tests in the research center); 2) Serum creatinine (Cr) > upper limit of normal (ULN) (refer to the normal range of laboratory tests in the research center);

[0082] (9) Other general conditions that are not suitable for participation in the study: 1) Those who have participated in and received drug / medical device intervention within 3 months before screening or are currently participating in any other clinical trials; 2) Those with a history of drug, alcohol or substance abuse; 3) Patients with severe neurological or mental illness who cannot fully understand and cooperate; 4) Women and male patients of childbearing age who are pregnant, breastfeeding, planning to become pregnant or have not taken reliable birth control measures, and are unwilling to take birth control methods during the trial and within 30 days after the last medication. Reliable birth control measures include: transdermal patches, intrauterine devices / systems (IUD / IUS), oral, implantable or injectable contraceptives, abstinence and spousal vasectomy, use of condoms, etc.; 5) Those who are unable to comply with the requirements of the study protocol; 6) Those who are otherwise deemed unsuitable for participation in clinical trials by the researchers.

[0083] 3.3 Treatment methods

[0084] The observation group received Huatansan granules, one bag at a time, twice a day; the control group received pentoxyverine citrate tablets, one tablet at a time, three times a day. Both treatment courses lasted two weeks.

[0085] 3.4 Observation and follow-up

[0086] The two groups filled out the sputum viscosity score sheet before treatment (baseline period) and after treatment (follow-up period), and observed and recorded the sputum viscosity of the two groups of patients before and after treatment.

[0087] 3.5 Efficacy Analysis

[0088] Sputum viscosity score:

[0089] Markedly effective: Sputum viscosity score ≥70% after treatment. Effective: Sputum viscosity score ≥30% and <70% after treatment. Ineffective: Sputum viscosity score <30% after treatment.

[0090] Note: The formula for calculation using the nimodipine method is: sputum viscosity score (n) = (sputum viscosity score before treatment - sputum viscosity score after treatment) / sputum viscosity score before treatment × 100.

[0091] Table 4 Sputum viscosity scoring table

[0092]

[0093] 3.6 Research Process

[0094] Patients in both groups were required to undergo visits before and after treatment, fill out sputum viscosity scoring forms, and undergo statistical analysis.

[0095] 3.7 Experimental Results

[0096] A total of 42 patients with chronic bronchitis and expectoration who met the inclusion criteria were enrolled. During treatment, two patients dropped out of the treatment group. Ultimately, 40 patients were included in the statistical analysis, with 20 patients in each treatment and control groups. The results showed that Huatan San effectively improved sputum viscosity in both the treatment and control groups (p < 0.01).

[0097] Table 5 Comparison of comprehensive efficacy after treatment with Huatansan

[0098]

[0099] Table 6 Total scores of sputum viscosity before and after intervention in the two groups

[0100]

[0101] The results listed in the above table show that the important composition of the present invention has a good therapeutic effect on chronic bronchitis with phlegm-heat blocking the lungs, coughing up thick sputum, chest tightness and qi reversal.

[0102] The above specific embodiments are not intended to limit the scope of protection of the present invention. For those skilled in the art, any substitution, improvement, or modification of the embodiments of the present invention falls within the scope of protection of the present invention. Any details not described in the present invention are generally known to those skilled in the art.

Claims

1. A Chinese medicine composition for relieving cough and reducing phlegm, characterized in that: The invention is prepared from the following raw materials in parts by weight: 9-11 parts of Peucedanum chinense, 9-11 parts of Platycodon grandiflorum, 7-9 parts of Rhizoma Zingiberis, 8-10 parts of Radix Glehniae and 9-15 parts of Pumice.

2. The Chinese medicine composition for relieving cough and reducing phlegm according to claim 1, characterized in that The medicated remedy is prepared from the following raw materials in parts by weight: 9 parts of Peucedanum chinense, 9 parts of Platycodon grandiflorum, 9 parts of Rhizoma Zingiberis, 9 parts of Radix Glehniae and 9 parts of Pumice.

3. The Chinese medicine composition for relieving cough and reducing phlegm according to claim 1, characterized in that The oral preparation is prepared, and the oral preparation is oral liquid, granules, freeze-dried powder, tablets, capsules or pills.

4. A method for preparing the Chinese medicine composition for relieving cough and reducing phlegm according to claims 1-3, characterized in that: The oral preparation is a lyophilized powder, and its preparation method is as follows: A1 Take Tianzhuhuang slices, place them in a casserole, add 12 times the amount of water and soak for 30 minutes; A2: Place Platycodon grandiflorum, Peucedanum chinense, Rhizoma Zingiberis, and Pumice in another casserole, add 12 times the amount of water, and soak for 30 minutes; A3 decocts the soaking liquid with medicinal herbs in A1, brings it to a boil over high heat, then simmers it for 10 minutes. Add the soaking liquid with medicinal herbs in A2 to the casserole and simmer together, brings it to a boil over high heat, then simmers it for 20 minutes, and filters it while it is hot. A4: Add 10 times the amount of water to the residue obtained in A3, boil over high heat, then simmer for another 20 minutes. Filter while hot, combine the filtrate with the filtrate in A3, concentrate at 60°C, and freeze-dry in a vacuum oven to obtain the product.

5. A method for preparing the Chinese medicine composition for relieving cough and reducing phlegm according to claims 1-3, characterized in that: The oral preparation is a granule, and its preparation method is as follows: it is prepared from granules of Peucedanum chinense, Platycodon grandiflorum, Rhizoma Zingiberis, Radix Glycyrrhizae, and Pumice.

Images